KR20250003657A - 만성 폐 동종이식편 기능장애 치료를 위한 벨루모수딜 - Google Patents

만성 폐 동종이식편 기능장애 치료를 위한 벨루모수딜 Download PDF

Info

Publication number
KR20250003657A
KR20250003657A KR1020247036230A KR20247036230A KR20250003657A KR 20250003657 A KR20250003657 A KR 20250003657A KR 1020247036230 A KR1020247036230 A KR 1020247036230A KR 20247036230 A KR20247036230 A KR 20247036230A KR 20250003657 A KR20250003657 A KR 20250003657A
Authority
KR
South Korea
Prior art keywords
subject
belumosudil
cycle
lung
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036230A
Other languages
English (en)
Korean (ko)
Inventor
코레이 에스. 커틀러
재커라이어 마이클 디필립
해숙 티. 김
Original Assignee
카드몬 코포레이션, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카드몬 코포레이션, 엘엘씨 filed Critical 카드몬 코포레이션, 엘엘씨
Publication of KR20250003657A publication Critical patent/KR20250003657A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247036230A 2022-04-19 2023-04-18 만성 폐 동종이식편 기능장애 치료를 위한 벨루모수딜 Pending KR20250003657A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US63/332,628 2022-04-19
US202263389444P 2022-07-15 2022-07-15
US63/389,444 2022-07-15
PCT/US2023/018952 WO2023205153A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Publications (1)

Publication Number Publication Date
KR20250003657A true KR20250003657A (ko) 2025-01-07

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036230A Pending KR20250003657A (ko) 2022-04-19 2023-04-18 만성 폐 동종이식편 기능장애 치료를 위한 벨루모수딜

Country Status (11)

Country Link
US (1) US20250255867A1 (https=)
EP (1) EP4511036A1 (https=)
JP (1) JP2025513240A (https=)
KR (1) KR20250003657A (https=)
CN (1) CN119031914A (https=)
AU (1) AU2023256541A1 (https=)
CA (1) CA3249201A1 (https=)
IL (1) IL316410A (https=)
MX (1) MX2024012802A (https=)
TW (1) TW202404602A (https=)
WO (1) WO2023205153A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325938A (en) * 2023-07-17 2026-03-01 Kadmon Corp Llc Combination therapy including BTK inhibitor and BELUMOSUDIL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
WO2023205153A1 (en) 2023-10-26
JP2025513240A (ja) 2025-04-24
US20250255867A1 (en) 2025-08-14
CN119031914A (zh) 2024-11-26
TW202404602A (zh) 2024-02-01
AU2023256541A1 (en) 2024-12-05
CA3249201A1 (en) 2023-10-26
IL316410A (en) 2024-12-01
EP4511036A1 (en) 2025-02-26
MX2024012802A (es) 2024-11-08
AU2023256541A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Glassberg Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape
Hoeper et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
US10577414B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
ERSSON et al. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study
KR20250088633A (ko) (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
KR20250003657A (ko) 만성 폐 동종이식편 기능장애 치료를 위한 벨루모수딜
US20260027116A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Pidala et al. Carfilzomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium pilot phase II trial
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
Huang et al. Disseminated Fusarium solani infection in a child with acute lymphocytic leukemia: a case report and literature review
RAPOR Acute eosinophilic pneumonia secondary to heroin inhalation
He et al. Voriconazole successfully treats intracranial Trichosporon asahii infection in an immunocompetent patient: a rare case report and literature review
WO2025208442A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
Jose et al. Convalescent plasma therapy: A novel approach to a novel coronavirus
Karwa et al. Mucormycosis: A lethal disease
TW202533829A (zh) 用於治療anca相關性血管炎的因子b抑制劑
Ramezaninejad et al. The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial
Lipworth et al. Real-World Studies in Infrequently Exacerbating Patients With COPD
Zhang et al. Clinical Characteristics, Treatment Response and Outcomes of Bronchiolitis Obliterans Syndrome in Children with Hematologic Malignancies Undergoing Haploidentical Hematopoietic Cell Transplantation with G-CSF/ATG-Based Protocol: A Single-Center Study
Sherpa et al. A Rare Case of Anomalous Origin of Right Pulmonary Artery with PDA and Features of Eisenmenger Syndrome in 40-Year-Old Nepalese Male
CN119546306A (zh) 施用贝舒地尔以治疗慢性移植物抗宿主病的方法
Evans RA prevention trials seek to stop clinical onset of disease
Baughman et al. Postgraduate Course ERS Copenhagen 2005-Therapeutic options for interstitial lung diseases in 2005
Chiu et al. Pneumocystis carinii Infection in a Renal Transplant Recipient Presented asWalking Pneumonia Occurring 18 Years After Transplantation: A Case Report.
US20210393664A1 (en) Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000